4//SEC Filing
Gollob Jared 4
Accession 0001193125-25-239144
CIK 0001815442other
Filed
Oct 13, 8:00 PM ET
Accepted
Oct 14, 5:11 PM ET
Size
11.8 KB
Accession
0001193125-25-239144
Insider Transaction Report
Form 4
Gollob Jared
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2025-10-13$1.31/sh+800$1,048→ 120,800 total - Exercise/Conversion
Common Stock
2025-10-13$2.08/sh+673$1,400→ 121,473 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-13−800→ 28,999 totalExercise: $1.31Exp: 2028-10-31→ Common Stock (800 underlying) - Sale
Common Stock
2025-10-13$60.00/sh−3,114$186,840→ 118,359 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-13−673→ 22,210 totalExercise: $2.08Exp: 2029-05-22→ Common Stock (673 underlying)
Footnotes (2)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person.
- [F2]The shares underlying this stock option are fully vested and exercisable.
Documents
Issuer
Kymera Therapeutics, Inc.
CIK 0001815442
Entity typeother
Related Parties
1- filerCIK 0001821198
Filing Metadata
- Form type
- 4
- Filed
- Oct 13, 8:00 PM ET
- Accepted
- Oct 14, 5:11 PM ET
- Size
- 11.8 KB